TYK Medicines, Inc (HKG:2410)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
11.10
-0.09 (-0.80%)
At close: Mar 10, 2026
-63.73%
Market Cap 4.25B
Revenue (ttm) 117.25K
Net Income (ttm) -306.91M
Shares Out 380.07M
EPS (ttm) -0.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,552,000
Average Volume 2,093,987
Open 11.24
Previous Close 11.19
Day's Range 11.08 - 11.37
52-Week Range 9.85 - 46.10
Beta n/a
RSI 34.95
Earnings Date Mar 27, 2026

About TYK Medicines

TYK Medicines, Inc., a clinical-stage biopharmaceutical company, research, development and commercialization of pharmaceutical products. Its lead product candidate is TY-9591, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of brain metastases from non-small cell lung cancer (NSCLC) with EGFR mutations, and in locally advanced or metastatic NSCLC with EGFR L858R mutation. The company also develops TY-302, an oral cyclin-dependent kinase (CDK) 4/6 inhibitor to treat solid tumors, including b... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Employees 163
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2410
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.